These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 30250989)
1. Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV Azad GK; Cousin F; Siddique M; Taylor B; Goh V; Cook GJR Mol Imaging Biol; 2019 Aug; 21(4):781-789. PubMed ID: 30250989 [TBL] [Abstract][Full Text] [Related]
2. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [ Azad GK; Taylor BP; Green A; Sandri I; Swampillai A; Harries M; Kristeleit H; Mansi J; Goh V; Cook GJR Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):821-830. PubMed ID: 30506455 [TBL] [Abstract][Full Text] [Related]
3. Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of Azad GK; Siddique M; Taylor B; Green A; O'Doherty J; Gariani J; Blake GM; Mansi J; Goh V; Cook GJR J Nucl Med; 2019 Mar; 60(3):322-327. PubMed ID: 30042160 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Prospective Study of Serial Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233 [TBL] [Abstract][Full Text] [Related]
6. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer. Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210 [TBL] [Abstract][Full Text] [Related]
7. The correlation of Qu YH; Long N; Ran C; Sun J Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540 [TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806 [TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. De Giorgi U; Mego M; Rohren EM; Liu P; Handy BC; Reuben JM; Macapinlac HA; Hortobagyi GN; Cristofanilli M; Ueno NT J Nucl Med; 2010 Aug; 51(8):1213-8. PubMed ID: 20660382 [TBL] [Abstract][Full Text] [Related]
10. Makhlin I; Korhonen KE; Martin ML; Gillman J; Schubert E; Pantel AR; Mankoff DA; Clark AS Radiol Imaging Cancer; 2022 Nov; 4(6):e220032. PubMed ID: 36269154 [TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575 [TBL] [Abstract][Full Text] [Related]
12. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT]. Moragas M; Soler M; Riera E; García JR Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280 [TBL] [Abstract][Full Text] [Related]
13. Intra-tumor metabolic heterogeneity of gastric cancer on Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Ulaner GA; Eaton A; Morris PG; Lilienstein J; Jhaveri K; Patil S; Fazio M; Larson S; Hudis CA; Jochelson MS Cancer Med; 2013 Oct; 2(5):725-33. PubMed ID: 24403238 [TBL] [Abstract][Full Text] [Related]
15. Metabolic Tumor Burden Assessed by Dual Time Point [ Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471 [TBL] [Abstract][Full Text] [Related]
16. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N; Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775 [TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649 [TBL] [Abstract][Full Text] [Related]
19. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262 [TBL] [Abstract][Full Text] [Related]
20. 18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma: a pilot study. Sharma P; Karunanithi S; Chakraborty PS; Kumar R; Seth A; Julka PK; Bal C; Kumar R Nucl Med Commun; 2014 Dec; 35(12):1247-53. PubMed ID: 25171438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]